Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS first tertiary institution in SA to form association with the Arbinger Institute
2008-02-15

 

 A two-day seminar entitled: "The Choice and The Choice @ Work" was recently presented in Bloemfontein to companies in the Free State region. Here are, from the left: Mr Braam Botha (Well @ Work), Mr Jozef Myburgh (Telkom), and Dr Cobus Pienaar (from the Department of Industrial Psychology at the UFS and facilitator of the Arbinger Programme).
Photo: Lacea Loader

 

UFS first tertiary institution in SA to form association with the Arbinger Institute

The University of the Free State (UFS) has become the first tertiary institution in the country to form an association with the Arbinger Institute in the United States of America (USA).

“The Arbinger Institute is a global management training and consulting firm applying the implications of self-deception and its solutions to all aspects of organisational performance. Our association with this Institute is a major step for the development of leadership in the country,” says Mr Danie Jacobs, Head of the Centre for Business Dynamics at the UFS.

Dr Cobus Pienaar, from the Department of Industrial Psychology at the UFS, is currently the only licensed facilitator to present Arbinger’s work in South Africa. Dr Pienaar presents The Choice and The Choice @ Work programme on behalf of the Centre for Business Dynamics, under the banner of the UFS School of Business.

According to Mr Jacobs, the programme has already had successes in South Africa. “Dr Pienaar presented the first programme last year in Bloemfontein and Pretoria to leaders from various companies. The feedback on the application of the programme to the South African business environment was phenomenal,” says Mr Jacobs.

The Arbinger Institute’s change work grows out of the scholarly work of philosopher Terry Warner. With an international team of scholars, Warner has broken new ground in solving the age-old problem of self-deception, or what was originally called “resistance”.

“This phenomenon is at the heart of much organisational failure. It is the reason why many organisational problems seem so intractable at their core – they are in self-deception; they resist solution,” says Mr Jacobs.

Media release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
15 February 2008

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept